VOOPOO
7.1.2022 13:02:14 CET | Business Wire | Press release
At the start of the new year 2022, VOOPOO , always in pursuit of unique industrial designs, has made another big move. On January 5, it launched Vinci Pod Royal Edition with a new relief design. Its shining and lightweight overall shape emphasizes a retro feel while also showing a strong aristocratic atmosphere.
Original relief craftsmanship for Pod
A large number of relief artworks have been unearthed from the ancient Sumerian Ruins, one of the birthplaces of human civilization. In contemporary times, there are also plenty of art products using relief craftsmanship. According to Vivian, Head of VOOPOO Product Development Team, “It is precisely the ancient relief artworks and the fashionable and retro contemporary elements that inspired us to develop the Vinci Pod Royal Edition series. Our original purpose is to explore the artistic and cultural value of the Pod product itself, so that users can also show their artistic taste in the process of using the product.”
However, it is no easy to engrave relief patterns on delicate Pod products. Any slight fault in the process will result in failure to achieve art-grade quality. The six products of the VOOPOO Vinci Pod Royal Edition series are all designed by experienced artists and are also integrated with design elements from retro jazz and cool graffiti styles. Product development took 8 months, and 12 manufacture processes and 68 techniques were involved, with 80% of the work completed by hand. The products were a result of the collaboration of more than 20 people including industrial designers, structural designers, and R&D members.
In addition to the unique relief itself, the tactile experience brought by the relief is even more impressive. Since the relief pattern of each product is different, customers can choose according to their own visual and tactile preferences. When the Pod of "tactile beauty" is held in your hand, you can experience an artistic masterpiece with its concave-convex surface, allowing you to enjoy a noble experience at your fingertip.
Focused on the user's product experience
In addition to the appearance, the product’s material and user experience also fit the users’ habits. The VOOPOO product development team has chosen the 6061 aviation-grade aluminum alloy, which boasts excellent strength, plasticity, fracture toughness, fatigue resistance, stress corrosion cracking resistance and exfoliation corrosion resistance, and has been widely used in aerospace, high-speed rail and automotive industries. It is worth noting that after 268 precise airflow experiments, the transmitter and airway design of VINCI Pod Royal Edition has been well optimized, bringing unparalleled comfort to the mouth-sucking experience.
VINCI Pod Royal Edition comes with the visual VINCI POD cartridge, which allows users to see the remaining e-liquid in real time, so that they can refill in time and refrain from anxiety. At the same time, VINCI Pod Royal Edition is equipped with 0.8Ω and 1.2Ω atomizers for users to enjoy different levels of taste and nicotine experience according to their preferences. VINCI Pod Royal Edition has also perfectly integrated the breathing light, so that it lights up when the user is inhaling, and goes off when stopping, providing users the strong dynamic sense.
WARNING: This product may be used with e-liquid products containing nicotine. Nicotine is an addictive chemical.
Voopoo website: https://www.voopoo.com/
IG: https://www.instagram.com/voopoo_global/
https://www.instagram.com/voopootechofficial/
Facebook: https://www.facebook.com/Voopootech/
Tiktok: https://www.tiktok.com/@voopoo_indonesia?lang=en
Please view the original press release at businesswire.com: https://www.businesswire.com/news/home/20220105006068/zh-CN/
The original source-language text of this announcement is the official, authoritative version. Translations are provided as an accommodation only, and should be cross-referenced with the source-language text, which is the only version of the text intended to have legal effect.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220105006058/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom